Royalty Pharma (RPRX) Free Cash Flow Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 31.42% |
| 10 | Royalty Pharma | 25.75 Bn | 25.14 Bn | - | -14.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.95% |
| Dec 31, 2025 | -33.63% |
| Sep 30, 2025 | 30.66% |
| Jun 30, 2025 | -3.19% |
| Mar 31, 2025 | 8.94% |
| Dec 31, 2024 | -8.21% |
| Sep 30, 2024 | 17.24% |
| Jun 30, 2024 | -30.07% |
| Mar 31, 2024 | 192.88% |
| Dec 31, 2023 | 1.39% |
| Sep 30, 2023 | 34.20% |
| Jun 30, 2023 | 242.08% |
| Mar 31, 2023 | 5.14% |
| Dec 31, 2022 | 201.53% |
| Sep 30, 2022 | -58.24% |